273 related articles for article (PubMed ID: 20446016)
1. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
3. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.
Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F
Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646
[TBL] [Abstract][Full Text] [Related]
4. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
5. Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery.
Stummer W; Meinel T; Ewelt C; Martus P; Jakobs O; Felsberg J; Reifenberger G
J Neurooncol; 2012 May; 108(1):89-97. PubMed ID: 22307805
[TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Norden AD; Lesser GJ; Drappatz J; Ligon KL; Hammond SN; Lee EQ; Reardon DR; Fadul CE; Plotkin SR; Batchelor TT; Zhu JJ; Beroukhim R; Muzikansky A; Doherty L; Lafrankie D; Smith K; Tafoya V; Lis R; Stack EC; Rosenfeld MR; Wen PY
Neuro Oncol; 2013 Jul; 15(7):930-5. PubMed ID: 23553268
[TBL] [Abstract][Full Text] [Related]
8. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
[TBL] [Abstract][Full Text] [Related]
9. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
10. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
[TBL] [Abstract][Full Text] [Related]
13. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.
Penas-Prado M; Hess KR; Fisch MJ; Lagrone LW; Groves MD; Levin VA; De Groot JF; Puduvalli VK; Colman H; Volas-Redd G; Giglio P; Conrad CA; Salacz ME; Floyd JD; Loghin ME; Hsu SH; Gonzalez J; Chang EL; Woo SY; Mahajan A; Aldape KD; Yung WK; Gilbert MR; ;
Neuro Oncol; 2015 Feb; 17(2):266-73. PubMed ID: 25239666
[TBL] [Abstract][Full Text] [Related]
15. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
[TBL] [Abstract][Full Text] [Related]
16. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
17. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
[TBL] [Abstract][Full Text] [Related]
18. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
[TBL] [Abstract][Full Text] [Related]
19. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
20. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.
Makino K; Nakamura H; Hide T; Kuratsu J
J Neurooncol; 2012 Jan; 106(1):155-60. PubMed ID: 21720808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
